Clinical Trial News and Research

RSS

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

Immune Network Ltd. advises that Immunitor will present latest results from its imm01 clinical trial in tuberculosis patients in Abuja, Nigeria at the 18th Union TB and Lung Diseases Conference of the African Region, 2nd to 5th March, 2011.

28 Feb 2011

MEPs, OETC visit new TB vaccine trial site to express support for candidate development

Emergent BioSolutions Inc. announced that a joint delegation of Members of the European Parliament and representatives from the Oxford-Emergent Tuberculosis Consortium today visited the trial site where MVA85A, the world's most clinically advanced tuberculosis vaccine candidate in development, is being studied in a Phase IIb infant efficacy clinical trial.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has treated the first patient in a pilot clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

28 Feb 2011

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.

25 Feb 2011

Medwell commits $2,000,000 investment in Mimetogen

Medwell Capital Corp. today announced that it has committed to invest up to $2,000,000 in Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately-held, clinical-stage company developing a treatment for dry eye disease. Medwell Capital participated in a Series B equity financing with existing Mimetogen investors, iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica.

25 Feb 2011

ICTS concludes enrollment months ahead of schedule for rheumatology study

ICTS, the patient recruitment and clinical trial services company, has successfully completed the fifth in a series of rheumatology study recruitment efforts for the same sponsor. Using an integrated approach that centered around a study website, social media, geographically initiated keyword search advertising, and also included site enrollment toolkits, the program exceeded the enrollment timelines established by the sponsor.

25 Feb 2011

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

A U.S.-Chile collaboration is bringing surgical patients closer to having a long-acting local anesthetic. In a randomized, double-blind trial, patients given neosaxitoxin, a new local anesthetic derived from algae, had significantly less postoperative pain and recovered about two days sooner than those given the commonly used local anesthetic bupivacaine.

25 Feb 2011

Enrollment commences in NORDIC implantable cardioverter defibrillator clinical trial

BIOTRONIK SE & Co. KG announced today the start of the NORDIC ICD clinical trial. The first implantable cardioverter defibrillator (ICD) patients were enrolled by its coordinating clinical investigator, Prof. Dr. Dietmar Bänsch at the University Hospital of Rostock and the investigator Dr. Stefan Kuster at the DRK Hospital of Mölln/Ratzeburg.

25 Feb 2011

Savient launches KRYSTEXXA in the U.S.

Savient Pharmaceuticals, Inc. announced the official full U.S. commercial launch of KRYSTEXXA™ (pegloticase), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.

25 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

$MHI begins patient enrollment for new device to treat refractory angina$

MHI begins patient enrollment for new device to treat refractory angina

The interventional cardiology team at the Montreal Heart Institute recently began patient enrolment for a new device, the Neovasc Reducer, designed to treat patients suffering from refractory angina.

25 Feb 2011

BSD announces inclusion of hyperthermia and chemotherapy for high-risk sarcoma cancer patients

BSD Medical Corporation today announced the inclusion of hyperthermia and chemotherapy as a recommended cancer treatment for Stage IV sarcomas in the "Practice Guidelines in Oncology", which is issued by the National Comprehensive Cancer Network.

25 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

PhRMA: 460 medicines in development for rare diseases

America's biopharmaceutical research companies are intensifying research into rare diseases, which often are among the most devastating to patients and complex for researchers. A record 460 medicines for rare diseases are in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

24 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

Clinical Trial News and Research

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

MEPs, OETC visit new TB vaccine trial site to express support for candidate development

Researchers to examine thrombolysis for treatment of DVT in leg

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

Medwell commits $2,000,000 investment in Mimetogen

ICTS concludes enrollment months ahead of schedule for rheumatology study

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

Enrollment commences in NORDIC implantable cardioverter defibrillator clinical trial

Savient launches KRYSTEXXA in the U.S.

Research sheds new light on problem of insulin resistance in type 2 diabetes

MHI begins patient enrollment for new device to treat refractory angina

BSD announces inclusion of hyperthermia and chemotherapy for high-risk sarcoma cancer patients

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PhRMA: 460 medicines in development for rare diseases

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News